MetaCap

DaVita (DVA) vs Viemed Healthcare (VMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

DaVita (DVA) has outperformed Viemed Healthcare (VMD) over the past year, gaining 33.9% versus a gain of 27.9%. Over five years, DVA leads with a +65.5% price change compared with +62.9% for VMD. DaVita is the larger company by market cap ($10.13 billion vs $322.8 million), about 31.4 times the size, while Viemed Healthcare is growing revenue faster (+20.5% vs +6.5%).

On valuation, DaVita trades at a lower forward P/E (9.5x vs 21.3x for Viemed Healthcare). Viemed Healthcare converts more of its revenue into profit, with a net margin of 5.5% versus 5.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DVA+33.91%VMD+27.93%
+106%+43%-19%
Nov 21, 20251 yearNov 20, 2026
DVA+61.76%VMD+56.33%
+150%+55%-40%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DVA versus VMD key metrics
MetricDVAVMD
Share price$161.03$8.52
Market cap$10.13B$322.85M
1-day change+3.00%-1.05%
YTD return+41.74%+14.67%
1-year return+33.91%+27.93%
5-year return+65.52%+62.91%
P/E ratio (TTM)12.1922.42
Forward P/E9.5221.30
EPS (TTM)$13.21$0.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$13.64B$270.28M
Revenue growth (YoY)+6.46%+20.52%
Net income (latest FY)$746.80M$14.93M
Gross margin—57.52%
Operating margin14.98%8.49%
Net margin5.47%5.53%
52-week high$247.49$12.61
52-week low$101.00$6.60
Distance from 52-week high-34.93%-32.43%
Analyst consensusbuybuy
Avg. price target upside+38.04%+40.85%
Average volume738.70K247.43K
Shares outstanding62.90M37.89M
Employees78,0001,490
SectorHealth CareHealth Care
IndustryMisc Health and Biotechnology ServicesMisc Health and Biotechnology Services

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DaVita is about 31.4 times larger than Viemed Healthcare by market value ($10.13B vs $322.85M).
  • Viemed Healthcare trades at a higher earnings multiple (22.4x vs 12.2x trailing P/E).
  • Viemed Healthcare grew revenue faster in its latest fiscal year (+20.52% vs +6.46%).

About DaVita

DVA stock →

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.

Health Care · Misc Health and Biotechnology Services · 78,000 employees

About Viemed Healthcare

VMD stock →

Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.

Health Care · Misc Health and Biotechnology Services · 1,490 employees

DVA vs VMD FAQ

Which is bigger, DaVita or Viemed Healthcare?

DaVita (DVA) is larger, with a market capitalization of $10.13B compared with $322.85M for Viemed Healthcare (VMD).

Which stock has performed better over the past year, DVA or VMD?

DVA returned +33.91% over the past 12 months, compared with +27.93% for VMD (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, DVA or VMD?

DVA has the lower trailing P/E at 12.2, versus 22.4 for VMD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are DaVita and Viemed Healthcare in the same industry?

Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.

More comparisons